Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry

John J. Miles, Mai Ping Tan, Garry Dolton, Emily S.J. Edwards, Sarah A.E. Galloway, Bruno Laugel, Mathew Clement, Julia Makinde, Kristin Ladell, Katherine K. Matthews, Thomas S. Watkins, Katie Tungatt, Yide Wong, Han Siean Lee, Richard J. Clark, Johanne M. Pentier, Meriem Attaf, Anya Lissina, Ann Ager, Awen Gallimore & 7 others Pierre J. Rizkallah, Stephanie Gras, Jamie Rossjohn, Scott R. Burrows, David K. Cole, David A. Price, Andrew K. Sewell

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic "mimics" using subunits that do not exist in the natural world. We developed a platform based on D-amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus-specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.

LanguageEnglish
Pages1569-1580
Number of pages12
JournalJournal of Clinical Investigation
Volume128
Issue number4
DOIs
StatePublished - 2 Apr 2018

Cite this

Miles, J. J., Tan, M. P., Dolton, G., Edwards, E. S. J., Galloway, S. A. E., Laugel, B., ... Sewell, A. K. (2018). Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. Journal of Clinical Investigation, 128(4), 1569-1580. DOI: 10.1172/JCI91512
Miles, John J. ; Tan, Mai Ping ; Dolton, Garry ; Edwards, Emily S.J. ; Galloway, Sarah A.E. ; Laugel, Bruno ; Clement, Mathew ; Makinde, Julia ; Ladell, Kristin ; Matthews, Katherine K. ; Watkins, Thomas S. ; Tungatt, Katie ; Wong, Yide ; Lee, Han Siean ; Clark, Richard J. ; Pentier, Johanne M. ; Attaf, Meriem ; Lissina, Anya ; Ager, Ann ; Gallimore, Awen ; Rizkallah, Pierre J. ; Gras, Stephanie ; Rossjohn, Jamie ; Burrows, Scott R. ; Cole, David K. ; Price, David A. ; Sewell, Andrew K./ Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. In: Journal of Clinical Investigation. 2018 ; Vol. 128, No. 4. pp. 1569-1580
@article{dbd7a4b0602c477093706e881cd62ed3,
title = "Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry",
abstract = "Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic {"}mimics{"} using subunits that do not exist in the natural world. We developed a platform based on D-amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus-specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.",
author = "Miles, {John J.} and Tan, {Mai Ping} and Garry Dolton and Edwards, {Emily S.J.} and Galloway, {Sarah A.E.} and Bruno Laugel and Mathew Clement and Julia Makinde and Kristin Ladell and Matthews, {Katherine K.} and Watkins, {Thomas S.} and Katie Tungatt and Yide Wong and Lee, {Han Siean} and Clark, {Richard J.} and Pentier, {Johanne M.} and Meriem Attaf and Anya Lissina and Ann Ager and Awen Gallimore and Rizkallah, {Pierre J.} and Stephanie Gras and Jamie Rossjohn and Burrows, {Scott R.} and Cole, {David K.} and Price, {David A.} and Sewell, {Andrew K.}",
year = "2018",
month = "4",
day = "2",
doi = "10.1172/JCI91512",
language = "English",
volume = "128",
pages = "1569--1580",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

Miles, JJ, Tan, MP, Dolton, G, Edwards, ESJ, Galloway, SAE, Laugel, B, Clement, M, Makinde, J, Ladell, K, Matthews, KK, Watkins, TS, Tungatt, K, Wong, Y, Lee, HS, Clark, RJ, Pentier, JM, Attaf, M, Lissina, A, Ager, A, Gallimore, A, Rizkallah, PJ, Gras, S, Rossjohn, J, Burrows, SR, Cole, DK, Price, DA & Sewell, AK 2018, 'Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry' Journal of Clinical Investigation, vol. 128, no. 4, pp. 1569-1580. DOI: 10.1172/JCI91512

Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. / Miles, John J.; Tan, Mai Ping; Dolton, Garry; Edwards, Emily S.J.; Galloway, Sarah A.E.; Laugel, Bruno; Clement, Mathew; Makinde, Julia; Ladell, Kristin; Matthews, Katherine K.; Watkins, Thomas S.; Tungatt, Katie; Wong, Yide; Lee, Han Siean; Clark, Richard J.; Pentier, Johanne M.; Attaf, Meriem; Lissina, Anya; Ager, Ann; Gallimore, Awen; Rizkallah, Pierre J.; Gras, Stephanie; Rossjohn, Jamie; Burrows, Scott R.; Cole, David K.; Price, David A.; Sewell, Andrew K.

In: Journal of Clinical Investigation, Vol. 128, No. 4, 02.04.2018, p. 1569-1580.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry

AU - Miles,John J.

AU - Tan,Mai Ping

AU - Dolton,Garry

AU - Edwards,Emily S.J.

AU - Galloway,Sarah A.E.

AU - Laugel,Bruno

AU - Clement,Mathew

AU - Makinde,Julia

AU - Ladell,Kristin

AU - Matthews,Katherine K.

AU - Watkins,Thomas S.

AU - Tungatt,Katie

AU - Wong,Yide

AU - Lee,Han Siean

AU - Clark,Richard J.

AU - Pentier,Johanne M.

AU - Attaf,Meriem

AU - Lissina,Anya

AU - Ager,Ann

AU - Gallimore,Awen

AU - Rizkallah,Pierre J.

AU - Gras,Stephanie

AU - Rossjohn,Jamie

AU - Burrows,Scott R.

AU - Cole,David K.

AU - Price,David A.

AU - Sewell,Andrew K.

PY - 2018/4/2

Y1 - 2018/4/2

N2 - Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic "mimics" using subunits that do not exist in the natural world. We developed a platform based on D-amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus-specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.

AB - Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic "mimics" using subunits that do not exist in the natural world. We developed a platform based on D-amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus-specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.

UR - http://www.scopus.com/inward/record.url?scp=85045052493&partnerID=8YFLogxK

U2 - 10.1172/JCI91512

DO - 10.1172/JCI91512

M3 - Article

VL - 128

SP - 1569

EP - 1580

JO - Journal of Clinical Investigation

T2 - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -

Miles JJ, Tan MP, Dolton G, Edwards ESJ, Galloway SAE, Laugel B et al. Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. Journal of Clinical Investigation. 2018 Apr 2;128(4):1569-1580. Available from, DOI: 10.1172/JCI91512